Taiki Sato

Taiki Sato

Auto-generated profile, based on publicly available information

Taiki Sato

Department of Cardiovascular Medicine, Osaka University Graduate School of Medicine, Suita, Japan

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 February 2023 in Heart
Verified
Journal Article
Open access
PDF file
YSYohei Sotomi
Yohei Sotomi
SHShungo Hikoso
Shungo Hikoso
DNDaisaku Nakatani
Daisaku Nakatani
KOKatsuki Okada
Katsuki Okada
TDTomoharu Dohi
Tomoharu Dohi
YSYasushi Sakata
Yasushi Sakata
Objective Our previously established machine learning-based clustering model classified heart failure with preserved ejection fraction (HFpEF) into four distinct phenotypes. Given the heterogeneous pathophysiology of HFpEF, specific medications may have favourable effects in specific phenotypes of HFpEF. We aimed to assess effectiveness of medications on clinical outcomes of the four phenotypes using a real-world HFpEF registry dataset. Methods This study is a posthoc analysis of the PURSUIT-HFpEF registry, a prospective, multicentre, observational study. We evaluated the clinical effectiveness of the following four types of postdischarge medication in the four different phenotypes: angiotensin-converting enzyme inhibitors (ACEi) or angiotensin-receptor blockers (ARB), beta blockers, mineralocorticoid-receptor antagonists (MRA) and statins. The primary endpoint of this study was a composite of all-cause death and heart failure hospitalisation. Results Of 1231 patients, 1100 (83 (IQR 77, 87) years, 604 females) were eligible for analysis. Median follow-up duration was 734 (398, 1108) days. The primary endpoint occurred in 528 patients (48.0%). Cox proportional hazard models with inverse-probability-of-treatment weighting showed the following significant effectiveness of medication on the primary endpoint: MRA for phenotype 2 (weighted HR (wHR) 0.40, 95% CI 0.21 to 0.75, p=0.005); ACEi or ARB for phenotype 3 (wHR 0.66 0.48 to 0.92, p=0.014) and statin therapy for phenotype 3 (wHR 0.43 (0.21 to 0.88), p=0.020). No other medications had significant treatment effects in the four phenotypes. Conclusions Machine learning-based clustering may have the potential to identify populations in which specific medications may be effective. This study suggests the effectiveness of MRA, ACEi or ARB and statin for specific phenotypes of HFpEF. Trial registration number UMIN000021831.

1 June 2014 in Journal of Gastrointestinal and Liver Diseases
Verified
Journal Article
Open access
HSHideo Suzuki
Hideo Suzuki
MSMasashi Sato
Masashi Sato
DADaisuke Akutsu
Daisuke Akutsu
HSHiroaki Sugiyama
Hiroaki Sugiyama
TSTaiki Sato
Taiki Sato
YMYuji Mizokami
Yuji Mizokami
We report the case of a 58-year-old woman who was referred to our hospital due to frequent bloody mucus diarrhea. She was diagnosed with cap polyposis based on typical endoscopic and histological findings. Colonoscopy revealed multiple, reddish, mucus-capped polypoid lesions from the rectum to the sigmoid colon. A pathological examination revealed that the polyps were covered by erosive and inflamed granulation tissue with decreased crypt cells. Laboratory data indicated positive values for Helicobacter pylori immunoglobulin G antibody and hypoproteinemia. Metronidazole, H. pylori eradication, and levofloxacin therapies were not effective; however, the subsequent administration of betamethasone enema dramatically improved the clinical symptoms and endoscopic findings. The hypoproteinemia was normalized after the therapy. The dose of the betamethasone enema was tapered gradually, and no recurrence was observed 6 months after discontinuation of the treatment. This case suggests that betamethasone enema may be considered as the second treatment choice for cap polyposis patients after H. pylori eradication, metronidazole or levofloxacin therapy.

8 October 2020 in International Journal of Surgical Pathology
Verified
Journal Article
Closed access
PDF file
YSYoko Sato
Yoko Sato
TSTaiki Sato
Taiki Sato
JMJun Matsushima
Jun Matsushima
AFAkiko Fujii
Akiko Fujii
YOYuko Ono
Yuko Ono
SBShinichi Ban
Shinichi Ban
Some gastric epithelial neoplasms show predominant chief cell differentiation (oxyntic gland neoplasms), in which the entity of “gastric adenocarcinoma of fundic gland type” was firstly designated, whereas a possible more aggressive subgroup “gastric adenocarcinoma of fundic gland mucosa type” (GA-FGM) was subsequently proposed. However, the histopathologic progression mode of these neoplasms has not been sufficiently reported. In this article, we describe a case of GA-FGM in which we could observe its progression during 5 years. The tumor was removed by endoscopic submucosal dissection 5 years after the first biopsy, which had already shown a feature of oxyntic gland neoplasm. During the follow-up period, the endoscopy revealed little change in the tumor appearance. However, the histology of endoscopic submucosal dissection showed submucosal extension with its histological progression. Besides, other oxyntic gland neoplasms of the stomach were observed metachronously or synchronously, giving an implication about a common pathogenetic basis of these lesions.

24 December 2012 in Case Reports in Surgery
Verified
Journal Article
Open access
PDF file
TTToshihide Takahashi
Toshihide Takahashi
EIEiichi Ishikawa
Eiichi Ishikawa
YMYosuke Masuda
Yosuke Masuda
TYTetsuya Yamamoto
Tetsuya Yamamoto
TSTaiki Sato
Taiki Sato
AMAkira Matsumura
Akira Matsumura
Intracranial nongerminomatous germ cell tumors (NGGCTs) in unusual locations are extremely rare. Here, we report a case of a yolk sac tumor in the frontal lobe in a middle-aged patient. A 42-year-old man was admitted to our hospital for headache and nausea. Magnetic resonance imaging (MRI) showed an enhanced mass lesion with a marked cyst component. The serum alpha-fetoprotein (αFP) level was extremely high. Histological examination of specimens after subtotal removal revealed a primary mixed germ cell tumor with extensive yolk sac tumor elements, often referred to as an intracranial “yolk sac tumor.” The preoperative diagnosis of NGGCTs in unusual age and locations is extremely difficult. Clinicians should consider the possibility of NGGCTs, including yolk sac tumors, when intracranial tumors with unusual MRI findings are encountered.

3 March 2021 in Human Pathology: Case Reports
Verified
Journal Article
Open access
TSTaiki Sato
Taiki Sato
YOYuko Ono
Yuko Ono
JMJun Matsushima
Jun Matsushima
AFAkiko Fujii
Akiko Fujii
YSYoko Sato
Yoko Sato
SBShinichi Ban
Shinichi Ban
TAFRO (Thrombocytopenia, Anasarca, Fever and/or elevated C-reactive protein, Renal dysfunction or Reticulin fibrosis, and Organomegaly) syndrome is a unique systemic inflammatory disease, which has recently been proposed from Japan. We report a case showing TAFRO symptoms, the patient’s condition of which allowed histopathological examinations of several biopsy tissues including the kidney. A 37-year-old man was admitted to our hospital for evaluation of fever of unknown origin, pleural effusion and ascites, renal dysfunction, and lymphadenopathy. Serum IL-6 and VEGF were elevated. Histopathologic findings of the lymph node resembled those of mixed type Castleman disease. The bone marrow biopsy specimen revealed normocellular marrow with a mildly increased number of megakaryocytes, but without obvious fibrosis. The renal biopsy material showed glomerular microangiopathy with double contour of the capillary loops and mesangiolysis. In immunohistochemistry, VEGF was retained in podocytes, whereas IL-6 expression was not limited to the specific sites. Glomerular microangiopathy is regarded as a crucial change in TAFRO syndrome, which should be studied further with regard to VEGF and IL-6.

1 January 2021 in Nihon Rinsho Geka Gakkai Zasshi (Journal of Japan Surgical Association)
Verified
Journal Article
Open access
PDF file
TSTaiki Sato
Taiki Sato
HUHirohumi Uehara
Hirohumi Uehara
MTMakoto Tada
Makoto Tada
YKYoshiko Keira
Yoshiko Keira
AWAtsushi Watanabe
Atsushi Watanabe
症例は63歳,男性.16年前に当院で右下葉肺癌に対して右下葉切除+リンパ節郭清を施行(pT2N0M0扁平上皮癌)されている.術後5年無再発であり,定期経過観察は終了となっていた.健診での胸部X線写真で異常を指摘され,精査目的の胸部CTで右上葉S1b中心部に最大径28mmの一部充実部分を含むすりガラス状結節陰影を認め,気管支鏡下肺生検で肺腺癌の診断となった.cT1bN0M0 cStage I A2の診断で,中葉温存残存右肺上葉切除術を施行した.中葉の下縦隔への索状癒着を認め,中葉捻転防止策は不要であった.経過は順調で残存中葉の拡張に問題はなく,退院となった.病理病期はpT1c(4)N0M0 pStage IA3であり,術前に指摘し得なかった多発病変を認めた.術後の残存中葉の拡張は良好である.右上葉もしくは下葉切除後の中葉を温存した残存肺葉切除は中葉捻転が懸念されるが,術後癒着により捻転防止策は不要であった.